Aspen scraps dividend after difficult year, sees big opportunity in the sterile business


Aspen Pharmaceuticals has ruffled shareholders feathers after announcing it would not declare a final dividend for the first time in ten years. The drug maker saw headline earnings per share fall 15 per cent to 1254 cents but has managed to reduce its net debt by 27 per cent to R39 billion. CNBC Africa's Kopano Gumbi spoke to CEO Stephen Saad....